R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)
- Sponsor
- Konkuk University Medical Center
- Study ID
- NCT01427114
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- rituximab, cyclophosphamide, vincristine, and prednisolone — DRUG6 cycles of R-CVP followed by 2 cycles of rituximab
Study Details
The purpose of this study is to determine how efficient the combination of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II non-conjunctival ocular adnexal MALT lymphoma (OAML).
Key Dates
- Start date
- Jul 1, 2011
- Status verified
- May 2021
- Primary completion
- Aug 1, 2014
- Completion
- Jan 1, 2021
Study Design
- Enrollment
- 33 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: R-CVP6 cycles of R-CVP followed by 2 cycles of rituximab
Primary Outcome Measure
complete response rate [ Time Frame: 3 years ]
Related Studies
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling By Invitation · Stanford University · Stanford, California
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerRecruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina